Pretreatment Interstitial Lung Abnormalities Detected on... : Journal of Computer Assisted Tomography (original) (raw)

Chest Imaging

Pretreatment Interstitial Lung Abnormalities Detected on Abdominal Computed Tomography Scans in Prostate Cancer Patients

Kim, Hyun Jin MD∗; Jeong, Won Gi MD, PhD∗,†; Lee, Jeong Yeop MD∗,†; Lee, Hyo-Jae MD, PhD∗; Lee, Byung Chan MD, PhD∗,†; Lim, Hyo Soon MD, PhD∗,†; Kim, Yun-Hyeon MD, PhD∗

From the ∗Department of Radiology, Chonnam National University Medical School

†Department of Radiology, Chonnam National University Hwasun Hospital.

Received for publication June 5, 2023; accepted October 14, 2023.

Correspondence to: Won Gi Jeong, MD, PhD, Department of Radiology, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do, South Korea 58128 (e-mail: [email protected]).

The authors declare no conflict of interest.

Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.jcat.org).

Buy
SDC
Infographic

Abstract

Objective

Prostate cancer and interstitial lung abnormality (ILA) share similar risk factor, which is men and older age. The purpose of this study was to investigate the prevalence of pretreatment ILA among prostate cancer patients who underwent abdominal computed tomography (CT) within 1 year at their first visit to the urology department. In addition, we aimed to assess the association between pretreatment ILA and long-term survival in prostate cancer patients.

Methods

This study was conducted in patients who had a first visit for prostate cancer at urology department between 2005 and 2016 and underwent an abdominal CT within 1 year. A thoracic radiologist evaluated the presence of ILA through inspecting the lung base scanned on an abdominal CT. The association between pretreatment ILA and survival was assessed using Kaplan-Meier analysis with log-rank test. Specific survival rates at 12, 36, and 60 months according to the presence of ILA were evaluated using _z_-test. Cox regression analysis was used to assess the risk factors of mortality.

Results

A total of 173 patients were included (mean age, 70.23 ± 7.98 years). Pretreatment ILA was observed in 10.4% of patients. Patients with ILA were more likely to be older and current smokers. Pretreatment ILA was associated with poor survival (P < 0.001). Age ≥70 years (hazards ratio [HR], 1.98; 95% confidence interval [CI], 1.24–3.16; P = 0.004), metastatic stage (HR, 2.26; 95% CI, 1.36–3.74; P = 0.002), and ILA (HR, 1.96; 95% CI, 1.06–3.60; P = 0.031) were the independent risk factors of mortality. An ILA (HR, 3.94; 95% CI, 1.78–8.72; P = 0.001) was the only independent risk factor of mortality in localized stage prostate cancer patients.

Conclusions

This study provides important insights into the unexplored effect of pretreatment ILA in prostate cancer patients. Pretreatment ILAs were observed considerably in the lung bases scanned on the abdominal CT scans among prostate cancer patients. Furthermore, pretreatment ILAs were the risk factor of mortality. Therefore, lung bases should be routinely inspected in the abdominal CT scans of prostate cancer patients. This result may help clinicians in establishing personalized management strategy of prostate cancer patients.